Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2019—Ortho Clinical Diagnostics announced that its Vitros Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (Vitros HIV Combo test) has been granted FDA premarket approval for use on Ortho’s Vitros XT 7600 Integrated System. The Vitros HIV Combo is a fourth-generation test that detects HIV-1 and HIV-2 antibodies and the p24 antigen.
September 2019—MedTest Dx introduced at the 2019 American Association for Clinical Chemistry annual scientific meeting an improved line of Clinitox Calibrators and Controls for confirmation testing. The product line aims to provide laboratories performing drugs of abuse testing a comprehensive and reliable calibration and controls solution with extended shelf life and simplified documentation.
August 2019—The U.S. Food and Drug Administration authorized marketing of a diagnostic test to detect Zika virus immunoglobulin antibodies in human blood. The ZIKV Detect 2.0 IgM Capture ELISA (InBios, Seattle) is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies, including the InBios test, had been authorized only for emergency use.
August 2019—NeuMoDx Molecular launched its CE-IVD assays for hepatitis B virus and hepatitis C virus. The company also launched CE-IVD assays for cytomegalovirus and Epstein-Barr virus.
August 2019—Myriad Genetics announced that its BRACAnalysis CDx companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with olaparib (Lynparza, AstraZeneca) in the phase three POLO study. Results of the study were presented at the 2019 American Society of Clinical Oncology annual meeting in Chicago.
August 2019—Loop Genomics has expanded its kits and services capabilities to provide researchers with ultra-high resolution microbiome sequencing solutions using long reads on Illumina sequencers. The four kits are a low biomass (e.g. human skin) phased V1–V9 full-length 16S kit with picogram input amounts and zero human DNA background, a phased 18S-ITS1-ITS2 long-read solution for ultra-high
August 2019—Thermo Fisher introduced its Invitrogen Collibri DNA Library Prep Kits for high-throughput Illumina systems. The kits contain a tracking dye to provide an in-process visual cue, which aims to improve workflow success.
August 2019—Motic Digital Pathology released the latest version of the FS-Live Telepathology Suite for remote pathology consultation and diagnosis. The updated software upgrades FS-Live to load up to six slides at a time, for individual live viewing and remote control.
August 2019—Genentech announced that the FDA has granted accelerated approval to Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan (rituximab) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who have received at least two prior therapies. Accelerated approval was granted based on complete response rates observed in the phase one-b/two GO29365 study, a randomized, controlled clinical trial.
August 2019—The FDA approved lenalidomide (Revlimid, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma and previously treated marginal zone lymphoma.
